CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.791
NA - Nord America 3.765
AS - Asia 2.819
SA - Sud America 235
AF - Africa 68
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
AN - Antartide 1
Totale 10.690
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.720
CN - Cina 1.253
SG - Singapore 1.141
GB - Regno Unito 967
IT - Italia 518
RU - Federazione Russa 441
SE - Svezia 424
IE - Irlanda 368
DE - Germania 344
FR - Francia 322
BR - Brasile 201
FI - Finlandia 201
HK - Hong Kong 109
KR - Corea 102
UA - Ucraina 44
TG - Togo 42
VN - Vietnam 39
NL - Olanda 38
ID - Indonesia 33
CA - Canada 28
BE - Belgio 27
PL - Polonia 26
JP - Giappone 24
IN - India 20
AT - Austria 19
IR - Iran 13
TR - Turchia 13
CZ - Repubblica Ceca 12
MA - Marocco 9
MX - Messico 8
AZ - Azerbaigian 7
CH - Svizzera 7
CL - Cile 7
UZ - Uzbekistan 7
AR - Argentina 6
KZ - Kazakistan 6
PE - Perù 6
PK - Pakistan 6
EU - Europa 5
PH - Filippine 5
VE - Venezuela 5
AU - Australia 4
CO - Colombia 4
EG - Egitto 4
ES - Italia 4
IQ - Iraq 4
KG - Kirghizistan 4
NP - Nepal 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
AM - Armenia 3
DK - Danimarca 3
EC - Ecuador 3
LK - Sri Lanka 3
LT - Lituania 3
LV - Lettonia 3
PS - Palestinian Territory 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
ZA - Sudafrica 3
BM - Bermuda 2
CR - Costa Rica 2
GR - Grecia 2
IL - Israele 2
JO - Giordania 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LU - Lussemburgo 2
LY - Libia 2
MY - Malesia 2
NO - Norvegia 2
PA - Panama 2
PY - Paraguay 2
SA - Arabia Saudita 2
SN - Senegal 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HN - Honduras 1
IM - Isola di Man 1
JM - Giamaica 1
KE - Kenya 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
Totale 10.690
Salva come PNG Salva come JPEG
Città #
Southend 901
Chandler 819
Singapore 663
Dublin 368
Woodbridge 297
Ashburn 279
Beijing 258
Jacksonville 195
Ann Arbor 181
Verona 145
Lawrence 125
Princeton 125
Wilmington 114
New York 106
Helsinki 104
Jinan 102
Hong Kong 101
Munich 100
Houston 73
The Dalles 69
Sindelfingen 64
Redmond 59
Shenyang 59
Tianjin 55
Nanjing 54
Hebei 50
Seoul 45
Lomé 42
Milan 39
Seattle 37
Washington 33
Nanchang 32
Santa Clara 32
Kent 31
Jakarta 30
Haikou 29
Zhengzhou 29
Hangzhou 28
Brussels 27
Los Angeles 27
Changsha 26
Council Bluffs 25
Guangzhou 25
Ningbo 25
Boardman 24
Dong Ket 22
Rome 21
Taiyuan 20
Taizhou 20
Dallas 19
Moscow 19
Tokyo 19
Falls Church 18
Jiaxing 17
Nuremberg 17
Frankfurt am Main 16
Redwood City 16
São Paulo 16
Amsterdam 15
Lappeenranta 15
London 15
Fuzhou 14
Toronto 14
Vienna 14
Norwalk 13
Bologna 12
Brno 12
San Francisco 12
Augusta 11
Lanzhou 11
Padova 10
Falkenstein 9
Lancaster 9
Ottawa 9
Trento 9
San Mateo 8
Belo Horizonte 7
Este 7
Shanghai 7
Tashkent 7
Baku 6
Chicago 6
Dearborn 6
Dongguan 6
Jyväskylä 6
Lima 6
Paris 6
Recife 6
Ardabil 5
Bussolengo 5
Clearwater 5
Curitiba 5
Fairfield 5
Isola della Scala 5
Kochi 5
Menlo Park 5
Porto Alegre 5
Bishkek 4
Boydton 4
Brugnera 4
Totale 6.637
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 191
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 162
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 148
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 131
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 128
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 128
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 125
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 120
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 117
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 111
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 110
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 110
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 110
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 109
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 109
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 106
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 106
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 103
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 100
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 97
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 96
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 96
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 93
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 92
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 92
Clinical meta-analyses of targeted therapies in adenocarcinoma. 88
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 88
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 85
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 85
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 85
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 83
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 83
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 82
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 82
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 82
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 80
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 80
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 80
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 80
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 78
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 77
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 76
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 76
Do immune checkpoint inhibitors need new studies methodology? 76
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 76
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 75
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 74
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 74
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 74
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 72
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 71
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 71
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 71
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 71
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 71
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 70
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 70
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 70
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 69
Muscle derangement and alteration of the nutritional machinery in NSCLC 69
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 69
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 69
Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma (SQLC). 67
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 67
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 66
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 66
Physical activity and exercise in lung cancer care: will promises be fulfilled? 66
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 66
Exercise levels and preferences in cancer patients: a cross-sectional study 66
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 66
A multimodal approach to cancer-related cachexia: from theory to practice 66
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 65
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 64
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 64
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 63
Sorafenib for lung cancer: is the "Battle" still open ? 62
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 62
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 62
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. 60
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 59
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm 59
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma 59
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 59
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 59
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 59
Cellular and molecular biology of small cell lung cancer: an overview 57
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 57
Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research 57
Exercise and anemia in cancer patients: could make the difference? 57
Exercise oncology: It is time to make a change 57
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 56
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives 56
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives 56
mTOR Cross-Talk in Cancer and Potential for Combination Therapy. 55
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 55
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities 55
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. 54
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 54
Kinesiology students' perception regarding exercise oncology: a cross-sectional study 53
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 53
Totale 8.006
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.971
article - articoli 51.827
book - libri 0
conference - conferenze 692
curatela - curatele 0
other - altro 210
patent - brevetti 0
selected - selezionate 0
volume - volumi 242
Totale 105.942
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020198 0 0 0 0 0 0 0 0 0 63 51 84
2020/2021815 92 127 35 112 99 88 29 16 24 24 122 47
2021/20221.080 60 292 8 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/20253.048 230 184 209 791 148 200 201 192 708 185 0 0
Totale 10.989